Collegium Pharmaceutical, Inc. (NASDAQ:COLL) EVP Shirley R. Kuhlmann Sells 26,067 Shares of Stock

Collegium Pharmaceutical, Inc. (NASDAQ:COLL) EVP Shirley R. Kuhlmann sold 26,067 shares of the company’s stock in a transaction dated Thursday, March 6th. The stock was sold at an average price of $28.50, for a total transaction of $742,909.50. Following the sale, the executive vice president now directly owns 108,137 shares in the company, valued at $3,081,904.50. This represents a 19.42 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available at this link.

Collegium Pharmaceutical Price Performance

Collegium Pharmaceutical stock opened at $29.80 on Friday. The business’s 50-day simple moving average is $30.78 and its 200 day simple moving average is $33.28. Collegium Pharmaceutical, Inc. has a 12-month low of $27.28 and a 12-month high of $42.29. The stock has a market cap of $938.28 million, a price-to-earnings ratio of 12.84 and a beta of 0.99. The company has a quick ratio of 0.88, a current ratio of 0.97 and a debt-to-equity ratio of 3.43.

Collegium Pharmaceutical (NASDAQ:COLL) last issued its earnings results on Thursday, February 27th. The specialty pharmaceutical company reported $1.63 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.54 by $0.09. Collegium Pharmaceutical had a return on equity of 104.67% and a net margin of 14.78%. The firm had revenue of $181.95 million for the quarter, compared to analysts’ expectations of $179.68 million. As a group, research analysts anticipate that Collegium Pharmaceutical, Inc. will post 5.62 earnings per share for the current year.

Analyst Ratings Changes

A number of research firms recently commented on COLL. HC Wainwright restated a “buy” rating and set a $50.00 price target on shares of Collegium Pharmaceutical in a research report on Friday, January 10th. Piper Sandler lowered their target price on Collegium Pharmaceutical from $37.00 to $36.00 and set a “neutral” rating for the company in a research note on Tuesday, February 4th. Finally, Needham & Company LLC raised Collegium Pharmaceutical from a “hold” rating to a “buy” rating and set a $46.00 price target for the company in a report on Friday, January 10th. One analyst has rated the stock with a hold rating and five have assigned a buy rating to the company. According to data from MarketBeat.com, Collegium Pharmaceutical presently has a consensus rating of “Moderate Buy” and an average target price of $43.60.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently added to or reduced their stakes in the business. New Age Alpha Advisors LLC acquired a new stake in shares of Collegium Pharmaceutical in the fourth quarter valued at approximately $40,000. TD Private Client Wealth LLC increased its holdings in shares of Collegium Pharmaceutical by 39.5% in the third quarter. TD Private Client Wealth LLC now owns 1,707 shares of the specialty pharmaceutical company’s stock valued at $66,000 after purchasing an additional 483 shares during the last quarter. KBC Group NV raised its position in shares of Collegium Pharmaceutical by 72.5% in the fourth quarter. KBC Group NV now owns 2,336 shares of the specialty pharmaceutical company’s stock valued at $67,000 after purchasing an additional 982 shares during the period. Virtus Fund Advisers LLC lifted its stake in shares of Collegium Pharmaceutical by 30.5% during the 4th quarter. Virtus Fund Advisers LLC now owns 2,419 shares of the specialty pharmaceutical company’s stock worth $69,000 after buying an additional 565 shares during the last quarter. Finally, Nisa Investment Advisors LLC boosted its holdings in shares of Collegium Pharmaceutical by 14.5% during the 4th quarter. Nisa Investment Advisors LLC now owns 2,493 shares of the specialty pharmaceutical company’s stock worth $71,000 after buying an additional 316 shares during the period.

Collegium Pharmaceutical Company Profile

Collegium Pharmaceutical, Inc, a specialty pharmaceutical company, engages in the development and commercialization of medicines for pain management. Its portfolio includes Xtampza ER, an abuse-deterrent, extended-release, and oral formulation of oxycodone for the management of pain severe enough to require daily, around-the-clock, long-term opioid treatment; Nucynta ER and Nucynta IR, which are extended-release and immediate-release formulations of tapentadol, indicated for the management of acute, severe, and persistent pain; Belbuca, a buccal film that contains buprenorphine; and Symproic, an oral formulation of naldemedine for the treatment of opioid-induced constipation in adult patients with chronic non-cancer pain.